Use of corticosteroids in sepsis and infectious diseases: a narrative review.

Critically ill patients with septic shock exhibit dysregulated host inflammatory responses. Critical illness-related corticosteroid insufficiency (CIRCI) has been recognized as a potential contributor to poor outcomes in critically ill patients. CIRCI is characterized by dysregulation of the hypothalamic-pituitary-adrenal axis, which results in a state of systemic inflammation through altered cortisol metabolism and tissue resistance to corticosteroids, all of which may lead to systemic inflammation. Based on these pathophysiological mechanisms, the beneficial anti-inflammatory effects of corticosteroids have been proposed and evaluated in several clinical trials. However, evidence of the beneficial effects of corticosteroids has been evolving for years. While some studies have demonstrated beneficial outcomes, such as accelerated shock reversal, reduced duration of mechanical ventilation, and reduced mortality, other studies have failed to demonstrate significant mortality benefits. Such disparity in studies suggests the heterogeneity of critical illnesses and the difficulty in identifying optimal indications for corticosteroids. Recent studies demonstrated the beneficial role of corticosteroids in patients with severe COVID-19 and community-acquired pneumonia. Given the evolving body of evidence, this review discusses the utility of corticosteroids in critically ill patients, including those with sepsis, septic shock, COVID-19, and severe community-acquired pneumonia.